Company starts enrolling for injectable product trials in Canada
Positive data from bone graft test gets Franklin company closer to crucial FDA approval
Sam Lynch has BioMimetic on a steady growth path. Next up: Two important product launches [From our print edition featured in Monday's City Paper]
Despite red ink on balance sheet, company tops analyst expectations
Private placement will be followed by larger rights offering
Lynch adopts trading plan to unload almost 1 percent of biotech's stock
Healthways stashing cash, Habitat's capital campaign, the state of biotech in Tennessee, today's the day for a swim in the Cumberland, and more...
Danish company invests more than $5M over three weeks
Also: Clarcor CFO sells big and Tennessee Commerce back in NASDAQ's good graces
After nosedive late yesterday, company responds to FDA and sees shares rocket forward
All Articles